PRP for the Treatment of Erectile Dysfunction (ED) (NCT04350125) | Clinical Trial Compass
CompletedPhase 1
PRP for the Treatment of Erectile Dysfunction (ED)
United States4 participantsStarted 2022-03-04
Plain-language summary
Researchers are trying to determine the safety and efficacy of Platelet Rich Plasma (PRP) in the treatment of Erectile Dysfunction (ED).
Who can participate
Age range45 Years – 65 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The patient must have given his informed and signed written consent
* The patient has ED for longer than 1 year but less than 5 years.
* The subject has a stable partner for at least 3 months.
* The patient is PDE5i responsive, meaning he is able to achieve and maintain an erection under the effect of the maximal dosage of PDE5i
* IIEF-EF, EHS, SEP 2+3, and GAQ Domain score of 17-20 Mild to moderate vascular erectile dysfunction: PSV \> 25 cm/sec
Exclusion Criteria:
The patient is participating in another study that may interfere with the results or conclusions of this study
* History of radical prostatectomy or pelvic cancer surgery
* Prior history of pelvic malignancies
* Prior pelvic radiation therapy
* Neurological disease which effects erectile function (Spinal cord injury, iatrogenic injury to the pelvic or cavernous nerves)
* Psychiatric disease which effects erectile function
* The patient is taking blood thinners
* History of Diabetes Mellitus
* History of Coronary Artery Disease
* Evidence Based Criteria: Doppler Clinical Exam ( PSV \< 25 cm/sec defined criteria for severe erectile dysfunction not likely to respond to approved medical therapies)
* Biochemical evidence of Hypogonadism (total Testosterone \< 300 ng/dL)